NCT07680738Completed
Transcranial Direct Current Stimulation for Fatigue, Mood, and Cognition in Multiple Sclerosis
Transcranial Direct Current Stimulation for Fatigue, Mood, and Cognition in Multiple Sclerosis: A Randomized, Double-Blind, Sham-Controlled, Crossover Trial
Source: ClinicalTrials.gov · Last updated 2 Jul 2026
Brief summary (registry, in English)
Multiple sclerosis (MS) is a chronic, inflammatory and disabling disease of the Cnetral Nervous System characterized by relapsing and / or progressive somatosensory, motor and vestibular clinical manifestations. Moreover, fatigue, depression, anxiety, and cognitive impairment are also present in most MS patients. These symptoms substantially impact quality of life and often show limited response to conventional pharmacological treatment. Transcranial direct current stimulation (tDCS) is a non-invasive technique that applies a weak direct current to the scalp via surface electrodes, modulating cortical excitability in a polarity-dependent manner. The objective of this study is to evaluate the efficacy and safety of tDCS for fatigue, depression, anxiety, and cognitive performance in patients with relapsing or progressive MS.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 38 (actual)
- First submitted
- 23 Jun 2026
- Start date
- 1 Aug 2023
- Primary completion date
- 30 Aug 2024
- Lead sponsor
- Universidad de Almeria
- Diseases
- Multiple sclerosis
- NCT number
- NCT07680738
What you commit to
- Study type: Interventional
- Participants enrolled: 38
- From 1 Aug 2023 to the primary completion date, 30 Aug 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- History of neuropsychiatric illness (including major depression, bipolar disorder, schizophrenia, or any anxiety disorder) prior to the onset of multiple sclerosis
- Current neuropsychiatric pharmacological treatment, including any antidepressant, anxiolytic, neuroleptic, or anticonvulsant medication
- Clinical relapse requiring corticosteroid treatment in the 3 months prior to enrollment
Other illness
- Diagnosis of neuromyelitis optica spectrum disorder (Devic's disease)
- Presence of any other central nervous system disease
- Disease duration greater than 10 years combined with an EDSS score of ≤ 2
- Visual impairment secondary to optic neuritis, internuclear ophthalmoplegia (oculomotor disorder), or any other uncorrected visual impairment that would affect task performance on cognitive assessments
Other
- Current pharmacological treatment for fatigue or depression
- Severe upper-limb motor deficit that would prevent task performance on neuropsychological assessments
Who the study is looking for
- Age 18-55 years at the time of enrollment
- Clinical diagnosis of Relapsing Multiple Sclerosis (RMS) or Progressive Multiple Sclerosis (PMS), with or without active progression, established per the 2014 McDonald diagnostic criteria
- Expanded Disability Status Scale (EDSS) score of 0-3 at the time of screening
- Time since initial MS diagnosis of at least 6 months
- Active fatigue symptoms reported by the participant for at least the 6 months prior to enrollment
Age in the registry: 18 years to 55 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Neurociencia Clínica Integral Coordinator of this site? Confirm its status | Mexico City | Mexico | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.